Which country does cabozantinib come from and its production background?

Cabozantinib is a targeted anti-cancer drug, mainly developed and marketed by the American biopharmaceutical company Exelixis Inc.. It is a tyrosine kinase inhibitor (TKI) with a multi-target mechanism. Exelixis, headquartered in California, USA, is an innovative company focused on targeted cancer therapy. It has long been committed to the development of new therapeutic drugs based on molecular signaling pathways. Cabozantinib is one of its major R&D achievements. It has been widely used in the treatment of various cancers since its launch and has important international academic and clinical value.

Caboozantinib was originally approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of advanced metastatic medullary thyroid carcinoma (MTC). With the release of further clinical trial results, the drug's indications have been gradually expanded to the field of solid tumors such as advanced kidney cancer (RCC), hepatocellular carcinoma (HCC) and differentiated thyroid cancer (DTC), becoming one of the key targeted drugs in the treatment of various malignant tumors today.

From the perspective of international business cooperation, cabozantinib has been promoted by multiple pharmaceutical companies in different countries and regions. It is sold under the brand names Cabometyx (tablets) and Cometriq (capsules) in the United States and is directly responsible for Exelixis; in Europe, the Middle East and Africa, the drug is jointly promoted by the French company Ipsen; and in Japan and other Asian markets, it is sold by Takeda Pharmaceuticals (Takeda). This global market layout of multi-country and cross-company collaboration reflects the important strategic value of cabozantinib on a global scale.

In terms of production, cabozantinib’s original drugs adopt highly standardizedGMP production processes, and have passed strict clinical data evaluation and have been approved by the drug marketing approval systems of multiple European and American regulatory agencies. This standardized R&D and manufacturing process ensures the efficacy and safety of drugs.

Reference:https://en.wikipedia.org/wiki/Cabozantinib